Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutations

Launched by INSTITUTE OF CANCER RESEARCH, UNITED KINGDOM · Mar 7, 2016

Keywords

ClinConnect Summary

The GENPROS clinical trial is investigating how men with rare gene mutations, which can increase the risk of prostate cancer, respond to diagnosis and treatment for this disease. Specifically, the study looks at men who carry mutations in certain genes (BRCA1, BRCA2, HOXB13, and those related to Lynch Syndrome) and compares their outcomes to men who do not have these mutations. This research is important because it will help us understand how genetics might affect treatment success and patient survival, ultimately guiding better care for those at higher risk of prostate cancer.

To participate in this trial, men aged 65 to 74 who have been diagnosed with prostate cancer can join if they either have a known gene mutation or do not carry any mutations in the specified genes. Participants will be asked to provide clinical information about their treatment and outcomes, and some may also provide a blood or saliva sample for further genetic testing if they agree. This study is currently recruiting, and the findings will be crucial for improving treatment strategies for prostate cancer patients with these genetic risks.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• * Men diagnosed with PCa are eligible if:
• • known carriers of germline mutations associated with PCa risk OR
• • known non-carriers of mutations in the genes above
• Exclusion Criteria:
• • patients under 18 years of age
• • patients who are unable to give informed consent
• • patients who cannot be traced (\<6 months follow-up) or whose clinical data are not available
• • patients whose genetic status is unknown